Zyprexa Fact Sheet
Eli Lilly; patent expiration 2011.
Schizophrenia, both short-term and maintenance treatment.
- Bipolar disorder, including manic or mixed episodes, and maintenance monotherapy. Approval specifically includes both monotherapy and combination treatment with lithium or Depakote.
- IM formulation indicated for treatment of agitation associated with schizophrenia and bipolar mania.
- Off-label use for a variety of disorders, including treatment-resistant depression, anxiety disorders, PTSD, general impulsivity/agitation, and insomnia.
D2 and 5HT 2 receptor antagonist.
- Oral tablets at 2.5 mg, 5 mg, 10 mg, 15 mg, and 20 mg
- Orally disintegrating “Zyprexa Zydis” tablets in 5 mg, 10 mg, 15 mg and 20 mg
- Intramuscular injectible Zyprexa in 10 mg vials
- Start most patients at 5-10 mg QD, may need to increase up to 30 mg per day or more.
- Recommended IM dose for treatment of acute agitation is 10 mg.
BLACK BOX WARNING: All atypicals may increase mortality in elderly patients by 1.7 times greater than placebo.
- Most common are somnolence, dry mouth, constipation, and weight gain.
- Weight gain: Substantial; 10-30 pounds weight gain is common.
- EPS: Akithisia and parkinsonism in 10-20% of patients, depending on dosing.
- Glucose/Lipids: Associated with new onset diabetes and hyperlipidemia; worse in this regard than all atypicals except for clozapine.
- EKG: No concerns.
- Prolactin level: Transient increase only.
- Pregnancy Category C.
Does not affect hepatic enzymes and thus does not affect metabolism of other drugs.
- However, the metabolism of Zyprexa is affected in the following ways:
- Smoking and Tegretol increase clearance by 40%-50%, decreasing effective dose.
- Luvox decreases clearance by 50-70%, increasing blood levels of Zyprexa.
- Half-life 1-2 days, greater in elderly patients.
Earn CME Credit Instantly!
Not quite ready for a one-year subscription to The Carlat Psychiatry Report? Need CME credits on a particular topic or on a tight deadline?
Try our A la Carte CME! You can buy single or multiple credits of continuing education, without committing to a year-long newsletter subscription.
Already an A la Carte subscriber? Click here to go to your a la carte page
Steve Balt Interviewed by NPR
Our own Steve Balt was interviewed on NPR's "Talk of the Nation" on psychiatry's shift toward drugs and away from talk therapy.
After 10 years at the helm of TCPR, Dr. Carlat has handed over editor-in-chief duties to Dr. Steve Balt. We’re excited to welcome him aboard! Read More...
The 2012 Carlat Atypical Antipsychotics Table is Now Available!
With all the atypicals on the market, it's hard to keep track of indications, dosages, and all the other relevant facts for each drug. Use this table for summaries on these meds, their uses, their side effects, and a whole slew of other information.
TCPR Continuing Education